1. Home
  2. SEI vs NUVB Comparison

SEI vs NUVB Comparison

Compare SEI & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEI
  • NUVB
  • Stock Information
  • Founded
  • SEI 2014
  • NUVB 2018
  • Country
  • SEI United States
  • NUVB United States
  • Employees
  • SEI N/A
  • NUVB N/A
  • Industry
  • SEI
  • NUVB Biotechnology: Pharmaceutical Preparations
  • Sector
  • SEI
  • NUVB Health Care
  • Exchange
  • SEI NYSE
  • NUVB Nasdaq
  • Market Cap
  • SEI 1.1B
  • NUVB 959.2M
  • IPO Year
  • SEI 2017
  • NUVB N/A
  • Fundamental
  • Price
  • SEI $26.87
  • NUVB $2.67
  • Analyst Decision
  • SEI Strong Buy
  • NUVB Strong Buy
  • Analyst Count
  • SEI 2
  • NUVB 6
  • Target Price
  • SEI $30.00
  • NUVB $6.33
  • AVG Volume (30 Days)
  • SEI 889.9K
  • NUVB 2.7M
  • Earning Date
  • SEI 02-16-2025
  • NUVB 11-06-2024
  • Dividend Yield
  • SEI 1.79%
  • NUVB N/A
  • EPS Growth
  • SEI N/A
  • NUVB N/A
  • EPS
  • SEI 0.43
  • NUVB N/A
  • Revenue
  • SEI $280,141,000.00
  • NUVB $2,162,000.00
  • Revenue This Year
  • SEI $9.54
  • NUVB N/A
  • Revenue Next Year
  • SEI $64.93
  • NUVB N/A
  • P/E Ratio
  • SEI $62.32
  • NUVB N/A
  • Revenue Growth
  • SEI N/A
  • NUVB N/A
  • 52 Week Low
  • SEI $6.59
  • NUVB $1.43
  • 52 Week High
  • SEI $32.61
  • NUVB $4.16
  • Technical
  • Relative Strength Index (RSI)
  • SEI N/A
  • NUVB 48.20
  • Support Level
  • SEI N/A
  • NUVB $2.51
  • Resistance Level
  • SEI N/A
  • NUVB $2.87
  • Average True Range (ATR)
  • SEI 0.00
  • NUVB 0.17
  • MACD
  • SEI 0.00
  • NUVB -0.02
  • Stochastic Oscillator
  • SEI 0.00
  • NUVB 30.77

About SEI SOLARIS ENERGY INFRASTRUCTURE INC

Solaris Energy Infrastructure Inc provides services in the oil and gas industry. Its solutions are Solaris software suite, Fluid management system, Automated control systems, Field services, Last mile management, Wet sand solutions, Power Solutions, and Integrated wellsite solution.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Share on Social Networks: